NASDAQ$RLAY
Relay Therapeutics Inc. · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Relay Therapeutics reported its first quarter 2025 financial results and corporate updates, highlighting extended cash runway into 2029 and progress in clinical trials.
Relay Therapeutics reported a net loss of $77.1 million for Q1 2025, with total revenue of $7.7 million. The company extended its cash runway into 2029 through strategic cost reductions and expects to fully fund key initiatives, including the ReDiscover-2 trial and vascular malformations clinical proof-of-concept data.
- Cash runway extended into 2029, expected to fully fund the Company meaningfully past topline data for ReDiscover-2 trial and through clinical proof-of-concept data in Vascular Malformations.
- Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025.
- Initiated Phase 1 RLY-2608 vascular malformations clinical trial in Q1 2025.
- Strategic cost reductions implemented, including an approximately 80% reduction in research run rate spend and a reduction in force by approximately 70 people.
Headline financials
Revenue & EPS history
Relay Therapeutics · Revenue · Quarterly
$7.7M
Revenue by segment
Relay Therapeutics · $25.2M total across 1 segment · Q3 2023
- License and Other Revenue$25.2M—100.0%
Forward guidance
Relay Therapeutics expects its current cash, cash equivalents, and investments to be sufficient to fund its operating expenses and capital expenditure requirements into 2029, enabling the funding of key initiatives including generating topline data from the ReDiscover-2 trial and clinical proof-of-concept data in vascular malformations.
Tailwinds
- Cash runway extended into 2029, providing long-term financial stability.
- Expected to fully fund the ReDiscover-2 trial and vascular malformations clinical proof-of-concept data.
- Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025.
- Advancement of Fabry and NRAS programs to Investigational New Drug application (IND) readiness.
- Continued advancement of ongoing triplet cohorts with RLY-2608 + fulvestrant + atirmociclib or ribociclib.
Headwinds
- Restructuring activities may be more costly or time-consuming than expected.
- Internal and external costs for ongoing and planned activities may be higher than expected.
- Potential for the company to use cash more quickly than expected.
- Risk of delays or pauses in current or planned clinical trials.
- Preliminary or interim results of preclinical or clinical trials may not be predictive of future or final results.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2025
+0.2%
Avg return
Earnings day
-0.4%
Avg return
5 days after
-0.5%
Avg return
30 days after
57%
13 / 23 earnings
Positive
+11.7%
Q4 2025
Best reaction
-19.5%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.7% | -2.5% | +11.1% | |
| Q4 2025 | +11.7% | +10.8% | +4.8% | |
| Q3 2025 | -7.4% | -5.5% | +17.6% | |
| Q1 2025 | -4.8% | -9.6% | -2.4% | |
| Q4 2024 | -13.3% | -14.9% | -27.5% | |
| Q3 2024 | +3.2% | +3.5% | -22.5% | |
| Q2 2024 | -6.8% | -5.6% | -8.6% | |
| Q1 2024 | +5.7% | +1.2% | -3.8% | |
| Q4 2023 | -4.6% | -1.8% | -25.7% | |
| Q3 2023 | +10.1% | +19.3% | +27.4% | |
| Q2 2023 | +7.8% | +3.5% | -3.2% | |
| Q1 2023 | +0.5% | -5.3% | +2.3% | |
| Q4 2022 | -3.6% | -8.8% | -13.5% | |
| Q3 2022 | -4.3% | -6.8% | -12.4% | |
| Q2 2022 | +3.8% | -1.6% | +31.7% | |
| Q1 2022 | -19.5% | -33.5% | -31.6% | |
| Q4 2021 | +11.5% | +17.4% | +40.1% | |
| Q3 2021 | +1.7% | +0.6% | -19.6% | |
| Q2 2021 | +1.0% | +0.2% | -1.7% | |
| Q1 2021 | +5.7% | +8.5% | +23.9% | |
| Q4 2020 | -2.3% | +2.0% | -13.5% | |
| Q3 2020 | +0.5% | +13.5% | +5.7% | |
| Q2 2020 | +8.0% | +5.3% | +8.5% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro